Phase 3 Papulopustular Rosacea Study
Recruiting in Palo Alto (17 mi)
+49 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Galderma R&D
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Research Team
MG
Michael Graeber, M.D.
Principal Investigator
Galderma R&D, LLC
Eligibility Criteria
Inclusion Criteria
The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe)
The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.
Treatment Details
Interventions
- CD5024 1% cream (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: CD5024Experimental Treatment1 Intervention
CD5024 1% Cream
Group II: CD5024 VehiclePlacebo Group1 Intervention
CD5024 Vehicle Cream
Find a Clinic Near You
Who Is Running the Clinical Trial?
Galderma R&D
Lead Sponsor
Trials
303
Recruited
60,700+
Flemming Ørnskov
Galderma R&D
Chief Executive Officer since 2019
MD, MPH
Baldo Scassellati Sforzolini
Galderma R&D
Chief Medical Officer
MD, PhD